Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Paul A. Heidenreich, Biykem Bozkurt, David Aguilar et al. · Journal of the American College of Cardiology · 2022 · 2.6K citations

Medicine, Cardiology, Clinical Cardiology +13

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A. McDonagh, Marco Metra, Marianna Adamo et al. · European Heart Journal · 2023 · 2.2K citations · Full text

Medicine, Cardiology, Internal Medicine +16

The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease

Yun‐Hee Youm, Kim Nguyen, Ryan W. Grant et al. · Nature Medicine · 2015 · 2.1K citations · Full text

Life Sciences, Immunology, Pharmacology +14